SanofiXSWX:SAN 87 Buyback Yield % is 5.40 as of Jun. 27, 2026, which is 1321% above its 10-year median of 0.38. GuruFocus rates XSWX:SAN with a GF Score™ of 87/100 and a GF Value™ of CHF104.30. The stock has 2 warning signs investors should review. Among 291 Drug Manufacturers companies, Sanofi ranks better than 96.56% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Sanofi's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SAN vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Sanofi's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Sanofi's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi (XSWX:SAN) has a Buyback Yield % of 5.40 as of Jun. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sanofi and its competitors. This is 1321% above median its historical median of 0.38. According to the industry distribution chart, Sanofi ranks #10 out of 291 companies in the Drug Manufacturers industry, placing it in the top 3.4%.
Is Sanofi's Buyback Yield % too high?
Sanofi's current Buyback Yield % of 5.40 is 1321% above median its 10-year median of 0.38. Based on the distribution chart, Sanofi ranks #10 out of 291 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #10 out of 291 companies for Buyback Yield %. This places Sanofi in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sanofi and its competitors. Sanofi's current Buyback Yield % is 5.40, which is 1321% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current Buyback Yield % of 5.40. The stock's GF Value™ is CHF104.30, compared to a current price of CHF73.20 — trading 29.8% below its estimated fair value. The current Buyback Yield % is 5.40, which is 1321% above median its 10-year median of 0.38. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current Buyback Yield % is 5.40 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (XSWX:SAN) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of CHF73.20 is trading 29.8% below its estimated GF Value™ of CHF104.30.
Key valuation signals for XSWX:SAN:
Buyback Yield %: 5.40 (1321% above median its 10-year median of 0.38)
GF Value™: CHF104.30 vs. price of CHF73.20 (29.8% below fair value)
No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score
Get the complete analysis for XSWX:SAN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SAN has been successfully added to your 
